Pharsight

Stiolto Respimat generic

Stiolto Respimat is a spray, metered; inhalation drug owned by Boehringer Ingelheim. This drug, which was first authorised for market use on 21 May, 2015, contains the active ingredients Olodaterol Hydrochloride and Tiotropium Bromide.

When will Stiolto Respimat generic be available?

Stiolto Respimat has 16 total patents, 4 of which have already expired. The remaining patents are set to expire on various dates, with the last one due to lapse on 16 October, 2030. This suggests that the Stiolto Respimat generic could potentially be released after this date, subject to the resolution of any outstanding patent disputes or extensions.

Stiolto Respimat uses

Stiolto Respimat is primarily used for the treatment of COPD and other respiratory complaints. Its effectiveness is largely due to the active ingredients Olodaterol Hydrochloride and Tiotropium Bromide, which work respectively as a long-acting beta2-adrenergic agonist and a muscarinic antagonist.

Stiolto Respimat patent expiration

Stiolto Respimat is protected by 16 patents, out of which 4 have expired. The remaining patents encompass various aspects of the drug, from its composition to its manufacturing process and delivery mechanism. The last patent is set to expire on 16 October, 2030, after which the Stiolto Respimat generic may be available. Below are the details of the patents:

EPO Oppostions filed on Stiolto Respimat

Stiolto Respimat dosage

Want to ask something?